Regarding its prognostic value, PD-L1 expression is widely recognized as an adverse prognostic factor in several malignancies, such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, and bladder cancer [38]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.